来源：环球网 日前，2025年度第九届海丝眼视光及小儿疑难眼病会议"国家级继续教育基地项目2025-07-02-004（国） ——近视防控能力提升暨小儿疑难眼病培训班"在泉州爱尔眼科医院学术报告厅隆重举行。 该会议由温州医科大学附属眼视光医院主办，湖南省湘江公益基金会支持，泉州爱尔眼科医院承办。旨 在汇聚国内顶尖眼科专家，围绕近视防控、斜视、弱视、先天性白内障、眼底疾病等热点议题，共同探 讨儿童青少年近视防控与小儿疑难眼病的防治策略，推动眼科医疗事业的高质量发展。 现场参会人员合影 精准帮扶显担当，名医下沉共护航 会议现场举行了"守护明眸 助力成长"——集善·视界同行公益项目启动仪式。该项目由中国残疾人福利 基金会与湖南爱眼公益基金会共同发起，由爱尔眼科医院集团福建省区承接实施。 作为一项专项慈善行动，该项目将精准帮扶贫困家庭中面临视力困难的儿童青少年，通过提供公益视力 检查、配镜资助及眼部疾病诊疗补贴等方式，切实减轻贫困家庭的医疗负担。未来，还将持续联动社会 各界力量，扩大帮扶范围，让慈善之光照亮更多需要帮助的家庭。 大会主席、泉州爱尔眼科医院副院长金丽文上台分享了"星光引路，为EYE同行——名医基层健康公 ...

今年7月，天津华厦眼科医院积极响应集团"光明行"公益号召，由白内障专科主任医师王伟娟远赴西藏 昌都市类乌齐县开展高原眼科公益检查。这场光明之约在十月迎来温暖的延续——来自西藏的活佛才仁 旺索与尼姑仁青措毛，跨越千里来到天津华厦眼科医院接受进一步治疗。 活佛才仁旺索自15岁起便饱受夜盲症困扰，双眼患有视网膜色素变性，眼底情况复杂，右眼更因白内障 仅存光感。在前期王伟娟主任的细致筛查与协调下，此次来津后，由我院白内障科学科带头人张红教授 亲自接诊并实施手术。张红教授是国内较早开展白内障超声乳化手术与屈光性白内障手术的专家，在该 领域具有深厚的学术造诣与丰富的临床经验。尽管患者眼底条件非常特殊，手术团队仍全力为其进行了 悉心治疗，整个过程顺利平稳，术后患者情况稳定，为其后续生活带来积极改善。 从盛夏的高原筛查到金秋的来津治疗，天津华厦眼科医院用专业与坚守，在雪域高原与渤海之滨架起了 一座光明桥，让爱与希望在这片土地上持续传递，温暖绽放。这份来自雪域高原的信任与祝福，也将激 励天津华厦眼科继续肩负"无论富贵贫穷，都要服务好每个病人，让每个人拥有一双健康明亮的眼睛"的 使命，将光明传递到更远的地方。 与此同时，同行的尼 ...

Core Viewpoint - The article highlights the controversy surrounding Aier Eye Hospital's charitable activities, suggesting that the company may be profiting from its donations through a mechanism that allows funds to flow back to its own accounts, raising ethical concerns about its operations [2][3]. Group 1: Charitable Activities and Controversies - Aier Eye Hospital has faced scrutiny for its charitable donations, with reports indicating a "left hand donates, right hand receives" model that potentially allows the company to profit from medical insurance funds [2][3]. - In 2025, Aier Eye Hospital ranked 19th on the "China Charity List" with total donations of 21.672 million yuan, but the legitimacy of these donations has been questioned [3]. - The company has been accused of requiring beneficiaries to seek treatment at its own facilities, leading to funds ultimately returning to Aier Eye Hospital [4]. Group 2: Financial Performance and Market Position - Aier Eye Hospital's financial performance has shown signs of stagnation, with a net profit of 2.051 billion yuan in the first half of 2025, reflecting a mere 0.05% increase year-on-year [8]. - The company's stock price has declined, closing at 12.55 yuan per share on October 17, 2025, which is a drop from 13.25 yuan at the beginning of the year, indicating a lack of market confidence [9][10]. - Despite aggressive acquisitions since 2011, Aier Eye Hospital's growth rate has slowed significantly, with 2024 marking the lowest annual growth rates in revenue and net profit [8][9]. Group 3: Regulatory Issues and Compliance - Aier Eye Hospital has faced multiple penalties for insurance fraud, with specific cases involving improper billing practices and violations of medical insurance regulations [6]. - The company has been linked to a pattern of complaints regarding its practices, including allegations of misleading patients into unnecessary surgeries under the guise of free medical services [5][6]. Group 4: Business Expansion and Asset Growth - Aier Eye Hospital has expanded aggressively through acquisitions, with total assets reaching 35.269 billion yuan by mid-2025, a significant increase from 1.722 billion yuan in 2011 [7]. - The company has made notable acquisitions, including a 12 billion yuan purchase of a European chain in 2017 and a 6.5 billion yuan acquisition in 2025 [7][8].

Group 1 - The core viewpoint of the articles highlights Huaxia Eye Hospital's significant improvements in ESG ratings, reflecting its commitment to sustainable development and social responsibility [1][2][3] - Huaxia Eye Hospital achieved notable advancements in various ESG ratings, including an upgrade from BBB to A in Wind ESG rating and from B to A- in the Shandao Ronglv rating within three years [1] - The company has integrated party leadership into its ESG strategy, focusing on talent development and organizational strengthening, with 119 party members involved in training and development initiatives [1] Group 2 - In 2024, Huaxia Eye Hospital's "Qiao Aixin·Guangming Xing" initiative screened over 100,000 individuals and provided free surgeries for more than 5,000 impoverished eye disease patients [2] - The company has been actively involved in international aid, responding to the Belt and Road Initiative by conducting medical assistance in countries like Myanmar, Nepal, and Cambodia, with 760 consultations and 135 surgeries completed in Cambodia in 2024 [2] - Huaxia Eye Hospital's systematic approach to ESG has positioned it favorably in the capital market, potentially creating a development moat that combines social value with commercial resilience [2][3]

Core Insights - The article emphasizes the growing importance of ESG (Environmental, Social, and Governance) ratings as a key metric for assessing corporate health and long-term competitiveness, with companies like Huaxia Eye Hospital demonstrating exceptional ESG governance performance [1][2]. ESG Ratings and Performance - Huaxia Eye Hospital achieved remarkable ESG ratings, ranking in the top 24% globally in the S&P Global Corporate Sustainability Assessment, surpassing industry averages in environmental, social, and governance dimensions [1]. - The company has seen significant improvements in various domestic ESG rating systems, with Wind ESG rating rising from BBB to A, and other ratings also reflecting upward trends [1]. Policy Guidance and Framework - In 2024, the Ministry of Finance and other departments released guidelines for corporate sustainability disclosures, marking a new phase of standardization in China's ESG development [3]. - The Shenzhen Stock Exchange issued self-regulatory guidelines for sustainability reporting, requiring companies to publish their sustainability reports by April 30, 2026 [3]. Internal Mechanisms and Governance - Huaxia Eye Hospital has integrated ESG governance into its corporate strategy, establishing a dedicated committee under the board to oversee ESG strategy formulation and execution [3]. - The company has developed a comprehensive sustainable development policy framework, including environmental protection policies and supplier conduct guidelines, to support its ESG practices [4]. Employee Development and Social Responsibility - The company places a strong emphasis on employee development, with a focus on talent cultivation and a commitment to gender equality in the workplace [5][6]. - Huaxia Eye Hospital actively protects the rights of female employees, ensuring equal pay and providing necessary support during maternity [7]. Community Engagement and Philanthropy - The company engages in significant social responsibility initiatives, including free surgeries for impoverished patients and training local medical teams in underserved areas [8]. - Huaxia Eye Hospital has participated in international aid efforts, providing medical assistance in countries like Cambodia and Nepal, and has been recognized for its impactful community service [8][9]. Risk Management and Innovation - The company has established a robust risk management system covering supply chain, medical quality, and information security to ensure stable operations [9]. - Huaxia Eye Hospital is advancing its technological capabilities through the deployment of smart medical platforms and innovative models, enhancing its operational efficiency and service delivery [9].

Core Viewpoint - The 2025 China International Digital Economy Expo highlighted the importance of digital economy and technology innovation, with Aier Eye Hospital Group being recognized as a leading player in the digital economy by ranking 385th in the TOP 500 list of digital economy enterprises in China [1][3]. Company Performance - Aier Eye Hospital achieved an outpatient volume of 9.2483 million in the first half of 2025, representing a year-on-year growth of 16.47%, and performed 879,000 surgeries, a 7.63% increase compared to the previous year [3]. - The company has established a "graded chain" model to address the uneven distribution of medical resources in China, creating a comprehensive eye care system that connects grassroots medical services efficiently [3]. Innovation and Technology - Aier Eye Hospital has invested significantly in research and development, creating an integrated innovation platform that includes multiple hospitals, educational institutions, and research centers, facilitating talent cultivation from undergraduate to doctoral levels [4]. - The company has built a big data center for eye health, leveraging extensive data from its global network of eye hospitals to enhance medical services through AI and digital solutions [4][5]. Digital Transformation - Aier Eye Hospital completed the construction of a "four-cloud" architecture covering over 700 eye care institutions, establishing a clinical database of 27 million cases and specialized databases for various eye diseases [5]. - The "Eye Health Big Data Platform" was recognized as a pilot demonstration project by the Ministry of Industry and Information Technology in 2022, setting a benchmark for data governance in the industry [6]. Mission and Vision - Aier Eye Hospital is committed to ensuring that everyone, regardless of wealth, has the right to eye health, emphasizing its mission to provide high-quality eye care services through continuous technological innovation and digital transformation [6].

10月11日上午，在厦门大学医学院建院29周年之际，厦门大学医学院眼科学系正式授牌成立。该学系由 华厦眼科医院集团本部厦门大学附属厦门眼科中心牵头，充分整合厦门大学及各附属医院的眼科人才及 优质医疗资源，致力于培养兼具临床医学与科研创新的高水平复合型眼科人才，力争将眼科学建设成为 特色鲜明、国内领先的高水平学科。眼科学系的核心管理团队同步组建。厦门大学附属厦门眼科中心总 院长黎晓新任系主任，厦门大学眼科研究所所长、附属厦门眼科中心名誉院长刘祖国任系常务副主任。 强强联合 构建新医科融合发展新高地 成立仪式上，中国科学院院士、厦门大学医学院院长韩家淮，国际眼科科学院院士、厦门大学附属厦门 眼科中心总院长黎晓新，华厦眼科医院集团副总裁赖玮琼分别致辞。厦门大学医管办主任、医学院党委 书记李峰宣读成立眼科学系文件。厦门大学医学院副院长李炜主持会议。 韩家淮院士对眼科学系的成立表示热烈祝贺并寄予厚望。他指出，临床学系是建立在临床医学一级学科 下的、以学科发展为中心的功能性学术机构，旨在推进科系合一，促进大学本部与附属医院、以及各附 属医院之间的融合发展。希望附属厦门眼科中心积极发挥带头引领作用，以学系建设为契机，加大教 ...

Group 1 - The core event is the "National Hospital Investor Reception Day" scheduled for October 30, where investors can interact with the company's CEO, hospital directors, and leading experts [2][3] - The theme of this year's event is "Intelligent Leadership in New Journey," focusing on showcasing the operational status of hospitals and the company's advancements in AI, new technologies, and services [2][3][4] - The event aims to deepen investors' understanding of the industry and the company, having been held annually since 2019, effectively creating a long-term channel for engagement [3][4] Group 2 - The company emphasizes that despite challenges such as consumer confidence and healthcare cost control, the fundamental characteristics of the ophthalmology sector remain strong, with a focus on digital ophthalmology and AI empowerment [3] - The event has a "zero-threshold" registration policy, allowing all investors, regardless of shareholding, to participate, fostering an inclusive environment for feedback and suggestions [4] - The company has a strong track record in investor relations, having received multiple awards for best practices and maintaining a consistent cash dividend policy, with a total dividend payout of 7.12 billion since its IPO [4]

Group 1 - The core theme of the upcoming "National Hospital Investor Reception Day" is "Leading the New Journey," focusing on showcasing the operational status of hospitals and the company's advancements in artificial intelligence, new technologies, and new services [1][2] - The event, scheduled for October 30, allows investors to engage directly with the CEO, hospital directors, and leading experts, promoting a deeper understanding of the industry and the company [1][2] - The company has successfully held this event annually since its tenth anniversary in 2019, enhancing investor understanding and gathering valuable feedback [2] Group 2 - The company aims to achieve dual improvements in efficiency and quality through digital ophthalmology, AI empowerment, smart hospitals, and organizational transformation, despite challenges such as consumer confidence and healthcare cost control [2] - The event has a "zero-threshold" registration policy, welcoming all investors regardless of shareholding status, and has previously engaged investors as "supervisors" to provide feedback on service quality [3] - The company has consistently prioritized investor relations, receiving multiple awards for best practices in investor relations management, and has distributed a total of 7.12 billion yuan in cash dividends since its IPO, which is eight times the raised capital [3]

证券日报网讯爱尔眼科（300015）10月17日在互动平台回答投资者提问时表示，外部环境存在诸多不确 定性，但潜在需求不断增长具有确定性。公司将不断提升技术、服务和品牌，以发展的确定性应对环境 的不确定性，未来将根据增长情况稳步提高分红力度，通过动态评估适时推出更多举措。 ...